MedTrace Logo

RABIOPRED - a Validation Study of Theranostic Test to PREDict Treatment Response of Anti-TNFα BIologicals in Rheumatoid Arthritis

NCT03016260 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 250

Last updated 2019-12-24

No results posted yet for this study

Summary

RABIOPRED is an in vitro non-invasive blood test, which aims to identify patients with rheumatoid arthritis (RA) who are not likely to respond to anti-TNFα and methotrexate combination therapy.

Conditions

Interventions

BIOLOGICAL

Infliximab

Anti-TNF alpha originator

BIOLOGICAL

Adalimumab

Anti-TNF alpha originator

BIOLOGICAL

Etanercept

Anti-TNF alpha originator

BIOLOGICAL

Golimumab

Anti-TNF alpha originator

BIOLOGICAL

Certolizumab Pegol

Anti-TNF alpha originator

BIOLOGICAL

Infliximab biosimilar

Anti-TNF alpha Infliximab biosimilars

BIOLOGICAL

Etanercept biosimilar

Anti-TNF alpha Etanercept biosimilar

BIOLOGICAL

Infliximab biosimilar

Anti-TNF alpha Infliximab biosimilar

Sponsors & Collaborators

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-12-31
Primary Completion
2019-12-20
Completion
2019-12-20

Countries

  • Czechia
  • France
  • Israel
  • Netherlands
  • Turkey (Türkiye)

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03016260 on ClinicalTrials.gov